9 completed, 1 active not recruiting, 1 terminated. 6 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 5, Active not recruiting 1 |
| Phase 2 | 6 | Completed 5, Terminated 1 |
Follow Volitinib: new trials by email Literature Review of Volitinib trials Research Report on Volitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors Biospecimen Collection, Magnetic Resonance Imaging, Savolitinib - Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 41 | 2018-11-27 | 2026-07-30 |
| Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment AZD6094, Docetaxel - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Samsung Medical Center | 2 | 2017-07-10 | 2019-12-30 |
| Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2016-07-25 | 2025-01-13 |
| MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Savolitinib, MEDI4736, Tremelimumab - Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma | Phase 2 | Completed | Queen Mary University of London | 69 | 2016-05-03 | 2024-11-04 |
| Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment Volitinib - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Samsung Medical Center | 16 | 2016-02-10 | 2022-06-15 |
| Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment AZD6094, docetaxel - Advanced Gastric Adenocarcinoma | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 7 | 2015-04-30 | 2022-06-15 |
| A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC Volitinib, gefitinib - Non-Small Cell Lung Cancer | Phase 1 | Completed | Hutchison Medipharma Limited | 64 | 2015-04-01 | 2020-04-24 |
| A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer Volitinib, Docetaxel - Gastric Cancer | Phase 1 | Completed | Hutchison Medipharma Limited | 25 | 2014-09-01 | 2016-04-08 |
| A Food Effect Phase I Study of the Volitinib in Healthy Subjects Volitinib - Food Effect, Health Subjects | Phase 1 | Completed | Hutchison Medipharma Limited | 25 | 2013-11-01 | 2019-05-14 |
| Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors Volitinib - Tumor | Phase 1 | Completed | Hutchison Medipharma Limited | 47 | 2012-02-01 | 2016-06-01 |
Carcinoma, Renal Cell (2) · Carcinoma, Non-Small-Cell Lung (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Glioma (1) · Medulloblastoma (1) · Neoplasms (1) · Rectal Neoplasms (1) · Stomach Neoplasms (1)
Hutchison Medipharma Limited (4) · National Cancer Institute (NCI) (3) · Samsung Medical Center (3) · Queen Mary University of London (1)
China (3) · South Korea (3) · United States (3) · Canada (2) · Australia (1) · United Kingdom (1)
Hui Gan, MD,Ph.D (1) · Jason Lickliter, MD,Ph.D (1) · Jin Li, Prof. (1) · John H Strickler (1) · Michael Millward, MD,Ph.D (1) · Ralph Salloum (1) · Sumanta K Pal (1) · Yilong Wu, Prof. (1)
PMID 33052556, PMID 33592176, PMID 36809050, PMID 37146227, PMID 39255440, PMID 39652198, PMID 41861260
U10CA180888 (1), UM1CA081457 (1), UM1CA186704 (1)